Noel and Nord inject subsuplisions once a week to lose weight in a new drug approved clinically in China

On December 16, the Drug Review Center (CDE) recently announced that Novo Nordiak AM833 (NNC0174-0833 injections) had obtained a default license for clinical trials to be developed for weight management in obese/overweight patients.
AM833 is a new type of pancreatic amyloid polypeptide (IAPP) similarity developed by Noor and NORD that is injected once a week under the skin.
IAPP, also known as amylin, is a peptide hormone released by the pancreas while eating, which is released at the same time as insulin.
the role of tryptoprene is to help the digestive process by helping to control the speed of digestion.
its main function is to help slow the digestion of food and the release of glucose into the bloodstream.
AM833 can reduce weight by reducing food intake.
a 26-week Phase II clinical study included 706 obese or overweight subjects with at least one obesity-related disease treated with AM833 (0.3 mg, 0.6 mg, 1.2 mg, 2.4 mg, 4.5 mg), liraglutide (3.0 mg) or placebo.
results showed that the study reached the main clinical endpoint, with patients in the AM833 4.5 mg dose group losing 10.8 percent of their body weight compared to the baseline and only 3.0 percent in the placebo group at week 26.
AM833 is safe and well-to-bear.
and Nord have conducted AM833 clinical studies in many countries.
: Medical Rubik's Cube NextPharma obesity is a chronic disease that requires long-term treatment and is associated with many serious health consequences and reduced life expectancy.
also brings many complications, including type 2 diabetes, heart disease, obstructive sleep apnea, chronic kidney disease, non-alcoholic fatty liver disease and cancer.
。